关于II型内漏管理及预防性栓塞作用的国际横断面调查
该国际横断面调查向全球80家主动脉专业中心的血管专家发放问卷,56人(70%)回复。结果显示II型内漏管理高度多样,76.8%认为现有文献证据不足以支持将预防性栓塞纳入临床实践,近90%有兴趣参与评估其安全性和有效性的多中心随机对照试验。
要点
- 仅12%的受访者认为II型内漏不影响EVAR的持久性。
- 76.8%认为现有文献证据不足以支持将预防性栓塞纳入临床实践。
核心结论
- 主动脉专家对II型内漏的管理高度多样,需要进一步证据明确何时及如何最佳治疗II型内漏,以及需要长期数据的稳健研究评估预防性栓塞在提高EVAR持久性中的潜在作用。
研究设计与样本
- 国际横断面问卷调查,问卷通过在线平台分发至全球80家主动脉专业中心的血管专家,80名接收者中56人(70%)回复。
主要发现
- 对于已存在的II型内漏,12%认为「任何瘤囊扩张」是干预指征,41%在瘤囊扩张>5 mm时干预,52%在瘤囊扩张>10 mm时干预,63%在此情况下行选择性栓塞。
- 仅3.6%的参与者报告在其超过30%的EVAR病例中常规进行预防性栓塞,42.9%从未进行该操作,53.6%在<30%的病例中进行预防性栓塞。
- 76.8%认为现有文献缺乏足够证据支持将预防性栓塞整合入临床实践,近90%表示有兴趣参与评估预防性栓塞安全性和有效性的多中心随机对照试验。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Type II endoleaks (TIIELs) commonly occur following endovascular aneurysm repair (EVAR). There is a lack of unified consensus regarding the management of TIIEL. Preemptive embolization is a potential method to reduce the risk for TIIEL, but its role is debated. We performed a survey among aortic experts internationally to assess perspectives on TIIEL management and the role of preemptive embolization. METHODS: A questionnaire was prepared covering aspects on effect of TIIEL on EVAR outcome, strategies to manage TIIEL, and attitudes toward preemptive embolization techniques. The questionnaire was distributed using an online platform among vascular specialists across 80 specialized aortic centers worldwide. RESULTS: Of 80 survey recipients, 56 (70%) responded. Only 12% of participants did not believe TIIEL to affect the durability of EVAR. Nearly 82.2% of respondents believed TIIEL increases the likelihood of reintervention. One-quarter agreed that TIIEL increases aortic-related mortality post-EVAR. For established TIIEL, 12% find "any sac expansion" to be an indication for intervention, while 41% would intervene at >5 mm sac expansion, and 52% at >10 mm sac expansion. Majority (63%) perform selective embolization in this setting. Only 3.6% of participants reported routinely conducting preemptive embolization in over 30% of their EVAR cases, while 42.9% never performed this procedure, and 53.6% performed preemptive embolization in <30% of cases. A substantial 76.8% believed that existing literature lacked sufficient evidence to support the integration of preemptive embolization into their clinical practice. Additionally, almost 90% expressed interest in participating in a multicenter randomized controlled trial evaluating the safety and efficacy of preemptive embolization. CONCLUSION: Management of TIIEL is highly diverse among aortic experts. There is a need for further evidence on when and how to best treat TIIEL, as well as robust studies with long-term data to assess the potential role of preemptive embolization in increasing the durability of EVAR.
引用
- Habib M, D'Oria M, Budtz-Lilly J, et al. International Cross-Sectional Survey on Management of Type II Endoleak and the Role of Preemptive Embolization. Ann Vasc Surg. 2025. PMID: 40064285. doi:10.1016/j.avsg.2025.02.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。